Rhythm Pharmaceuticals has ridden a powerful long term share price climb, which puts a spotlight on whether the current US$112.28 price is backed up by the business it generates from its MC4R focused obesity treatments and pipeline. With that kind of move behind it and fresh financing in place, the live question is how today’s market value lines up with the company’s sales base.
- Over the past 5 years the stock has delivered a gain of roughly 7x, which makes the link between Rhythm Pharmaceuticals’ market value and its revenue footprint especially important for anyone looking at the shares today.
- The amended license for bivamelagon and the new US$750m term loan may support future commercial expansion but they also reshape how much of Rhythm Pharmaceuticals’ eventual sales flows to licensors and lenders before shareholders.
- Your read on Rhythm Pharmaceuticals is one view; the desks covering it have another. See what analysts think Rhythm Pharmaceuticals's shares could be worth.
The issue now is whether the stock’s current price can be explained by its sales when framed against that backdrop.
If you want a second reference point alongside Rhythm Pharmaceuticals, consider using a focused stock screen built around our screener containing 19 high quality undiscovered gems.
Does Rhythm Pharmaceuticals Look Pricey on Sales?
P/S is often the cleaner yardstick for a biotech like Rhythm Pharmaceuticals where earnings and free cash flow are still being built out. On this score, the shares trade on a P/S of 27.7x, compared with about 9.6x for the wider biotechs group and 8.7x across closer peers, so the current tag asks you to pay a much higher price per dollar of recent sales than typical in the sector.
That gap looks even larger against a more tailored fair multiple that adjusts for Rhythm Pharmaceuticals’ growth profile, margins, size and risk. The current 27.7x level screens as overvalued on that framework. Because the amended bivamelagon license and US$750m loan load more obligations onto future revenue, the rich P/S level also means you are paying up for sales that will be shared with licensors and lenders before anything reaches equity holders. Explore the numbers behind Rhythm Pharmaceuticals's P/S valuation.
The Rhythm Pharmaceuticals Narrative: What Would Justify Today's Price?
Rhythm Pharmaceuticals' Simply Wall St Narratives pick up where the valuation questions leave off and highlight the specific growth, margin and earnings paths that would need to occur for the current share price to appear meaningfully higher or lower in hindsight. Each scenario links its implied number to a clear view of how revenue, profitability and risk could change, giving you a reference point you can revisit as new information appears on the Community page.
One of the top community narratives on Rhythm Pharmaceuticals: 16% undervalued
"Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction, with additional opportunities to expand its portfolio..."
Discover why this Narrative puts Rhythm Pharmaceuticals at 16% undervalued.
One more Rhythm Pharmaceuticals check that sits alongside the price tag
Price ratios tell you what the market is paying today, but professional models that map out where Rhythm Pharmaceuticals could be a few years from now offer a different lens on whether that sticker really lines up with the story. Explore where analysts expect Rhythm Pharmaceuticals to be in a few years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com